Skip to main content
SpringerLink
Log in

Are surface markers of cancer stem cells reliable factors for cancer treatment follow-up?

  • Brief Communication
  • Published:
Comparative Clinical Pathology Aims and scope Submit manuscript

Abstract

Recent studies have explained that cancer stem cells (CSCs) can both instigate and maintain tumours. As a result, they are a good choice for targeted therapy in the treatment of aggressive cancers, and their long-term assessment is essential for the follow-up of therapeutic agent efficacy. However, several studies have revealed that their detection on the basis of surface markers is challenging. In this area, there are two main questions. First, why are surface markers of the CSCs so difficult to detect in in vitro studies? Second, are CSCs’ surface markers reliable factors when assessing cancer treatment efficacy? In order to consider these questions, we made three assumptions: (1) CSCs can grow in environmental conditions and in vitro studies, (2) stress exists within in vitro conditions, and (3) isotope diversity in surface markers might lead to problems in reliable identification.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Bozorg-Ghalati F, Hedayati M (2015) Relationship between PI3K mutation and sodium-iodide symporter in anaplastic thyroid carcinoma. American J Cancer Sci 4:63–77

    Google Scholar 

  • Bozorg-Ghalati F, Hedayati M (2016) BRAF mutation and its effects on radioiodine uptake in patients with anaplastic thyroid carcinoma. American J Cancer Sci 5(1):22–33

    Google Scholar 

  • Bozorg-Ghalati F, Hedayati M, Dianatpour M (2017) CD133 as a biomarker of thyroid cancer stem cells. Int J Curr Res 9(5):51284–51291.

  • Haghpanah V, Fallah P, Naderi M, Tavakoli R, Soleimani M, Larijani B (2016) Cancer stem-like cell behaviour in anaplastic thyroid cancer: a challenging dilemma. Life Sci 1(146):34–39

    Article  Google Scholar 

  • He QZ, Luo XZ, Wang K, Zhou Q, Ao H, Yang Y, Li SX, Li Y, Zhu HT, Duan T (2014) Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem 33:173–184

    Article  CAS  PubMed  Google Scholar 

  • Kaiser J (2015) The cancer stem cell gamble. Science 347(6219):226–229

    Article  CAS  PubMed  Google Scholar 

  • Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CL, Rich JN (2015) Cancer stem cells in glioblastoma. Genes Dev 29(12):1203–1217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu R, Shen Y, Nan K, Mi B, Wu T, Guo J, Li M, Lv Y, Guo H (2015) Association between expression of cancer stem cell markers and poor differentiation of hepatocellular carcinoma: a meta-analysis (PRISMA). Medicine (Baltimore) 94(31):e1306

    Article  CAS  PubMed  Google Scholar 

  • Lobo NA, Shimono Y, Qian D, Clarke MF (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23:675–699

    Article  CAS  PubMed  Google Scholar 

  • Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M (2008) CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 8(8):784–804

    Article  CAS  PubMed  Google Scholar 

  • McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7:489–497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Norton K-A, Popel AS (2014) An agent-based model of cancer stem cell initiated avascular tumour growth and metastasis: the effect of seeding frequency and location. J R Soc Interface 11:640–743

    Article  Google Scholar 

  • Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumour cells? Cell Stem Cell 16(3):225–238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, Lim LY, Kong L, Li L, Duan W (2013) RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 330(1):84–95

    Article  CAS  PubMed  Google Scholar 

  • Waldron NN, Vallera DA (2013) An old idea tackling a new problem: targeted toxins specific for cancer stem cells. Antibodies 2:82–92

    Article  CAS  Google Scholar 

  • Wang L, Huang X, Zheng X, Wang X, Li SH, Zhang L, Yang Z, Xia Z (2013) Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemo radiotherapy. Int J Biol Sci 9(5):472–479

    Article  PubMed  PubMed Central  Google Scholar 

  • Yu Y, Flint A, Dvorin EL, Bischoff J (2002) AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 277(23):20711–20716

    Article  CAS  PubMed  Google Scholar 

  • Zhang D, Sun B, Zhao B, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, Leng X, Zhang C, Sun R, Chi J (2014) Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer 13:207–221

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Farzaneh Bozorg-Ghalati

  2. Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Farzaneh Bozorg-Ghalati & Mehdi Hedayati

  3. Stem Cell Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Mehdi Dianatpour

  4. Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    Mehdi Dianatpour

Authors
  1. Farzaneh Bozorg-Ghalati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehdi Hedayati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mehdi Dianatpour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farzaneh Bozorg-Ghalati.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

The assumptions described in this manuscript were extracted from PhD thesis of Farzaneh Bozorg-Ghalati with grant number 6066 that financially supported by Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bozorg-Ghalati, F., Hedayati, M. & Dianatpour, M. Are surface markers of cancer stem cells reliable factors for cancer treatment follow-up?. Comp Clin Pathol 26, 981–983 (2017). https://doi.org/10.1007/s00580-017-2504-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00580-017-2504-5

Keywords

Search

Navigation